I-Mab
I-Mab (IMAB) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for I-Mab (IMAB), covering cash flow, earnings, and balance sheets.
I-Mab (IMAB) Income Statement & Financial Overview
View the income breakdown for I-Mab IMAB across both annual and quarterly reports.
Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
R&D Expenses | $777000.00 | $6.03M | $4.47M | $22.80M |
SG&A Expenses | $4.49M | $7.34M | $7.94M | $11.87M |
Operating Expenses | $5.27M | $13.37M | $12.41M | $15.008M |
Total Costs & Expenses | $5.27M | $13.37M | $12.41M | $15.008M |
Interest Income | $1.87M | $2.20M | $2.45M | $1.92M |
Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
Depreciation & Amortization | $0.00 | $0.00 | $0.00 | $5.99M |
EBITDA | -$5.27M | -$12.10M | -$12.41M | -$15.008M |
EBITDA Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | -$5.27M | -$13.37M | -$12.41M | -$15.008M |
Operating Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
Other Income/Expenses (Net) | $2.12M | $2.53M | -$8.08M | -$34.48M |
Income Before Tax | -$3.15M | -$10.84M | -$20.49M | -$49.49M |
Income Before Tax Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
Income Tax Expense | $0.00 | $0.00 | $0.00 | -$42.68M |
Net Income | -$3.15M | -$9.06M | -$20.49M | $25.13M |
Net Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
EPS | -$0.05 | -$0.11 | -$0.25 | $0.31 |
Diluted EPS | -$0.05 | -$0.11 | -$0.25 | $0.31 |
Weighted Avg Shares Outstanding | $81.60M | $81.50M | $81.50M | $81.78M |
Weighted Avg Shares Outstanding (Diluted) | $81.60M | $81.50M | $81.50M | $80.93M |
The company's financials show resilient growth, with revenue advancing from $0.00 in Q2 2024 to $0.00 in Q1 2025. Gross profit remained healthy with margins at N/A in Q1 2025 compared to N/A in Q2 2024. Operating income hit -$5.27M last quarter, sustaining a consistent N/A margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$5.27M. Net income rose to -$3.15M, while earnings per share reached -$0.05. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan